VLS.AU Vita Life Sciences Ltd
- Market cap
- AUD 148M
- P/E
- 13.7x
- P/B
- 2.65x
- ROE
- 39.8%
- Dividend yield
- 4.12%
- Fundamental score
- 4.1/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is VLS.AU undervalued?
Graham numberVLS.AU trades 26.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vita Life Sciences Ltd fundamental analysis
18 of 22 checks passedROE 2/2
High return on equity (39.8%), above 20%.
ROA 1/1
Return on assets (27.6%) is above the industry median (-8.9%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (14.9%) is above the 5-year average (9.6% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (14.9%) is below the industry median (42.8%).
Revenue Growth 2/2
Revenue grew 11.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 77.1x against interest expense, well covered.
PE vs Market 1/1
PE (13.7x) is below the market median (15.0x).
PE vs Industry 1/1
PE (13.7x) is below the industry median (21.9x).
PBV 0/1
Price to book (2.6x) is above the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 36.3, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.42, above 1.
Dividend Yield 1/2
Dividend yield (4.3%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 58.3%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vita Life Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Mascot,…
Full company profileVita Life Sciences Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vita Life Sciences Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 37.9M | 37.7M | 41.2M | 42.5M | 46.5M | 57.1M | 66.9M | 74.2M | 79.5M | 93.3M | 193M |
| Gross Profit | 26.2M | 25.6M | 27.6M | 27.9M | 29.3M | 34.8M | 39.7M | 42.6M | 47.2M | 56.0M | 123M |
| Operating Income | 5.81M | 4.81M | 4.43M | 4.57M | 7.54M | 11.3M | 11.0M | 12.2M | 11.7M | 14.7M | 33.5M |
| EBITDA | 6.06M | 5.15M | 4.84M | 5.18M | 8.88M | 11.7M | 11.4M | 13.1M | 13.5M | 15.7M | 31.5M |
| Net Income | 3.34M | 2.86M | 2.44M | 3.14M | 6.09M | 8.29M | 7.08M | 9.08M | 8.78M | 10.4M | 22.2M |
| EPS | 0.06 | 0.05 | 0.04 | 0.06 | 0.12 | 0.16 | 0.13 | 0.17 | 0.16 | 0.18 | 0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 32.4M | 33.0M | 35.7M | 36.5M | 39.1M | 45.3M | 51.8M | 59.8M | 71.9M | 82.4M | 80.5M |
| Total Liabilities | 9.18M | 8.16M | 13.3M | 14.0M | 14.7M | 14.8M | 15.3M | 16.5M | 19.6M | 26.2M | 24.8M |
| Shareholders' Equity | 23.1M | 24.8M | 22.4M | 22.6M | 24.7M | 30.8M | 36.6M | 43.4M | 52.4M | 56.3M | 55.8M |
| Cash & Short-term Investments | 9.41M | 9.97M | 10.9M | 10.5M | 14.5M | 15.9M | 15.7M | 24.6M | 28.6M | 35.6M | 33.7M |
| Total Debt | 2.46M | 2.22M | 2.07M | 2.35M | 2.07M | 373K | 601K | 387K | 517K | 2.39M | 2.16M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.71M | 3.22M | 2.84M | 2.03M | 7.54M | 5.89M | 2.78M | 13.0M | 6.16M | 16.4M | 19.8M |
| Capital Expenditure | 2.23M | 193K | 372K | 579K | 89.0K | 155K | 139K | 660K | 198K | 570K | 1.27M |
| Free Cash Flow | 2.48M | 3.03M | 2.47M | 1.45M | 7.46M | 5.73M | 7.54M | 12.3M | 5.96M | 15.9M | 18.5M |
| Ratios | |||||||||||
| ROE | 14.5% | 11.6% | 10.9% | 13.9% | 24.7% | 27.0% | 19.4% | 20.9% | 16.8% | 18.6% | 39.8% |
| ROA | 10.3% | 8.7% | 6.8% | 8.6% | 15.6% | 18.3% | 13.7% | 15.2% | 12.2% | 12.7% | 27.6% |
| Net Profit Margin | 8.8% | 7.6% | 5.9% | 7.4% | 13.1% | 14.5% | 10.6% | 12.2% | 11.0% | 11.2% | 11.5% |
| Debt to Equity | 0.11x | 0.09x | 0.09x | 0.10x | 0.08x | 0.01x | 0.02x | 0.01x | 0.01x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vita Life Sciences Ltd dividends
- Dividend yield
- 4.12%
- Forward dividend
- 0.15 AUD
- Payout ratio
- 58.3%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | AUD 6.08M | 0.11 | 58.3% |
| 2024 | AUD 5.17M | 0.09 | 58.8% |
| 2023 | AUD 3.37M | 0.06 | 37.1% |
| 2022 | AUD 3.04M | 0.06 | 42.9% |
| 2021 | AUD 2.90M | 0.05 | 34.9% |
| 2020 | AUD 1.97M | 0.04 | 32.4% |
| 2019 | AUD 2.02M | 0.04 | 64.3% |
| 2018 | AUD 2.02M | 0.04 | 82.8% |
| 2017 | AUD 2.06M | 0.04 | 72.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:1 on Jul 1, 2009.
Who owns Vita Life Sciences Ltd
- Insiders 76.91%
- Institutions 5.47%
- Public & others 17.62%
- Shares outstanding 53.9M
- Free float 20.1M
Vita Life Sciences Ltd company profile
- Company name
- Vita Life Sciences Ltd
- Ticker
- VLS.AU
- ISIN
- AU000000VLS8
- Exchange
- Australian Securities Exchange
- Listed since
- Aug 8, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1-5 Chalmers Crescent, Mascot, NSW, Australia, 2020
- Phone
- 61 02 9545 2633
- Website
- vitalifesciences.com
About Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Mascot, Australia.
Vita Life Sciences Ltd management
5- Mr. Andrew W. O'KeefeMD & Director
- Mr. Chin Leng Khoo AGIA, C.A., C.P.A., M.B.A.CFO & Company Secretary
- Ms. Melissa PereiraHead of Marketing
- Mr. Shaun RutherfordChief Executive Officer of Herbs of Gold Australia
- Ms. K. S. BehChief Executive Officer of Vita Life Sciences Malaysia & Singapore